Company leaders touted lutetium-177's 6.6-day half-life, saying it is short enough for use with a variety of radiopharmaceuticals and long enough to minimize decay loss during preparation and shipping. They also said the isotope damages tumors when bound to disease-specific targeting therapeutics.

The isotope will be used at Point's Indianapolis facility in the manufacturing of its therapeutic radioligand therapies.